http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2404582-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f834ce5e3653300cfeee6fc9f68468f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_77594fa6623e2e16ed117b3d63f6e9b7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 |
| filingDate | 2007-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d373c4e4dab01dc8b6044fe5e8568c21 |
| publicationDate | 2013-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2404582-T3 |
| titleOfInvention | Methods and kits to diagnose growth hormone deficiency |
| abstract | A method of assessing pituitary-related growth hormone deficiency in a human or animal subject, the method comprising providing at least one post-administration sample of a subject to which HAib-D-Trp-D-gTrp-CHO has been orally administered (EP 1572), determine the level of growth hormone in the sample or samples and assess whether the level of growth hormone is indicative of pituitary related growth hormone deficiency in the subject by comparing the level of growth hormone in at least one sample post-administration with the level that can be found in an equivalent post-administration sample of a subject that is known to have no growth hormone deficiency and / or to the level that can be found in an equivalent post-administration sample of a subject that is known to have Pituitary-related growth hormone deficiency, where: the sample is a blood sample, a sample of serum or plasma sample; The level of growth hormone in the sample is measured using an immunoassay; one or more post-administration samples or samples taken after a time interval between 15 and 120 minutes are provided; and the amount of EP 1572 administered is between 18 and 75 mg. |
| priorityDate | 2006-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 221.